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ABSTRACT
Background
Current criteria for the selection of unrelated donors for hematopoietic cell transplantation
(HCT) include matching for the alleles of each human leukocyte antigen (HLA) locus within the
major histocompatibility complex (MHC). Graft-versus-host disease (GVHD), however, remains a
significant and potentially life-threatening complication even after HLA-identical unrelated
HCT. The MHC harbors more than 400 genes, but the total number of transplantation antigens
is unknown. Genes that influence transplantation outcome could be identified by using linkage
disequilibrium (LD)-mapping approaches, if the extended MHC haplotypes of the unrelated
donor and recipient could be defined.
Methods and Findings
We isolated DNA strands extending across 2 million base pairs of the MHC to determine the
physical linkage of HLA-A, -B, and -DRB1 alleles in 246 HCT recipients and their HLA-A, -B, -C,
-DRB1, -DQB1 allele-matched unrelated donors. MHC haplotype mismatching was associated
with a statistically significantly increased risk of severe acute GVHD (odds ratio 4.51; 95%
confidence interval [CI], 2.34–8.70, p , 0.0001) and with lower risk of disease recurrence (hazard
ratio 0.45; 95% CI, 0.22–0.92, p ¼ 0.03).
Conclusions
The MHC harbors genes that encode unidentified transplantation antigens. The three-locus
HLA-A, -B, -DRB1 haplotype serves as a proxy for GVHD risk among HLA-identical transplant
recipients. The phasing method provides an approach for mapping novel MHC-linked
transplantation determinants and a means to decrease GVHD-related morbidity after HCT from
unrelated donors.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e8 0059
PLoS MEDICINEIntroduction
A hallmark of the human genome is its organization into
segments or blocks of closely linked genetic variants that are
inherited as haplotypes on the same DNA strand of a
chromosome [1,2]. Genes that cause disease are located
within haplotypes, and they can be identiﬁed by testing the
association of disease with informative single nucleotide
polymorphisms (SNPs) and other genomic markers [3].
Intense efforts are in progress to deﬁne the linkage of SNPs
in genomic DNA, to specify the organization of SNPs into
haplotype blocks, and to identify the SNPs that could serve as
proxies for haplotype blocks (tagSNPs) [4,5]. This information
provides powerful tools for mapping genes that cause disease
[6]. When family studies are not available, haplotypes can be
inferred with statistical methods [7,8]. Because haplotypes
deﬁne not one, but many, physically linked markers, they
provide important information regarding traits or diseases
resulting from the additive effects of genetic variation that
may alter disease susceptibility or severity and response to
therapy [9–12].
Haplotypes of the human major histocompatibility com-
plex (MHC) can be deﬁned by using human leukocyte antigen
(HLA) alleles as highly polymorphic markers. In human
populations, multiple blocks of genetic variation in the MHC
are strongly associated with each other as extended hap-
lotypes [13–19]. Haplotypes that share the same HLA alleles
may also share discrete segments or blocks of highly
conserved sequences in strong positive LD with those HLA
alleles [13,19–21]. HLA haplotypes serve as a model system for
studies of disease association [22–26], but their biological
implications have not been deﬁned for solid organ and
hematopoietic cell transplantation (HCT) [27,28]. In HCT,
differences between polymorphic HLA antigens of the donor
and recipient stimulate alloimmune reactions that cause
graft-versus-host disease (GVHD) or graft rejection. HLA
genotypically identical siblings are preferred as donors
because the inheritance of identical MHC haplotypes by
descent includes identity for all variation within the two
parental MHC haplotypes. HLA-matched unrelated donors
can be used for HCT when a related donor is not available
[28–30]. The identiﬁcation of HLA-matched unrelated donors
is feasible because matching for two HLA loci will often
determine matching for the third, a consequence of a
phenomenon known as linkage disequilibrium (LD). HLA-
allele matching has been used as a surrogate for MHC
haplotype matching in an effort to reduce risks after
unrelated HCT [28–30]. Nevertheless, GVHD remains a
signiﬁcant and potentially life-threatening complication after
HLA-identical unrelated HCT [31].
Many of the more than 400 genes within the 7.6-million-
base pair MHC region have immune-related functions, but
the total number of transplantation antigens encoded within
the MHC remains unknown. The dense clustering and strong
LD of genes within the MHC could provide a framework for
mapping genes that cause GVHD, if the extended MHC
haplotypes of the unrelated donor and recipient could be
deﬁned. Current mapping strategies using selected tagSNPs
to deﬁne MHC haplotype blocks that average 18,000 base
pairs in length are not sufﬁcient to deﬁne extended MHC
haplotypes [14]. To overcome this limitation, we isolated
DNA strands extending across 2 million base pairs of the
MHC containing numerous haplotype blocks, and we then
deﬁned the HLA-A, B, DR haplotypes in recipients and their
HLA-matched unrelated transplant donors [32]. The risks of
post-transplant complications associated with haplotype
mismatching were measured.
Methods
Study Participants
Patients were eligible (a) if they received a myeloablative
conditioning regimen and T cell–replete HCT with bone
marrow or growth-factor-mobilized blood cells from an HLA-
A, -B, -C, -DRB1, -DQB1 allele-identical unrelated donor for
treatment of a blood disorder, and cyclosporine and
methotrexate for post-grafting immunosuppression; (b) if
lymphoblastoid cell lines were available from both the donor
and recipient; and (c) if they were heterozygous at HLA-B and
at HLA-A or HLA-DRB1. 246 patients met all three study
criteria. 42 other patients were excluded because they were
homozygous at two or all three loci (n ¼ 22), homozygous at
HLA-B (n¼5), or the HLA-A and -DRB1 allele genotyping was
ambiguous (n¼15); haplotyping of these pairs will be feasible
in the future when the method is developed to include
additional polymorphic loci. The institutional review board
of the Fred Hutchinson Cancer Research Center approved
the study, and informed consent was obtained from all
patients.
Donor HLA Selection Criteria
HLA-compatible unrelated donors were selected as pre-
viously described [33,34]. In the present study, retrospective
sequencing was performed to conﬁrm donor–recipient HLA-
A, -B, -C, -DRB1, -DQB1 allele identity and to determine HLA-
DPB1 alleles in 226 transplant pairs [33].
Haplotyping to Determine Linkage of HLA-A, -B, and -DRB1
Alleles
We previously described a novel DNA microarray method
to determine the physical linkage of HLA-A, -B, and -DRB1
alleles when family study is not available [32]. Genomic DNA
was extracted from lymphoblastoid cell lines under con-
ditions that minimize shearing and then hybridized to arrays
containing two oligonucleotide probes, each speciﬁc for the
two HLA-B alleles in the sample. The linked HLA-A and
-DRB1 alleles on the captured HLA-B allele-speciﬁc strands
were then genotyped by using oligonucleotide probes.
Relative probe hybridization signal intensities were quanti-
ﬁed with the aid of software dedicated to a ﬂuorescence
scanner and used to assign recipient and donor haplotypes.
A pair was deﬁned as MHC haplotype-matched if the HLA-A,
-B, and -DRB1 alleles were physically linked to each other on
the captured haplotype; a pair was deﬁned as MHC
haplotype-mismatched if the HLA-A, -B, or -DRB1 alleles
were in any other rearrangement (Figure 1). The laboratory
information was interpreted without knowledge of clinical
outcomes and vice versa. In all cases, MHC haplotypes
assigned by laboratory methods were concordant with those
deduced from informative family studies [32]. In the present
study, phase determination did not include consideration of
HLA-C, -DQB1, or -DPB1 loci. Analysis of these genes will be
feasible with future modiﬁcations of the haplotyping
method.
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e8 0060
MHC Haplotypes in TransplantationTransplantation Procedure
Patients were prepared for transplantation with the use of
myeloablative conditioning regimens [34] (Table 1). Pre-
transplant disease risk was categorized as low-, intermediate-,
or high-risk according to established criteria [34]. GVHD and
recurrent malignancy were assessed as previously described
[33]. In summary, conventional grading of acute GVHD
incorporates the presence of the disease and its peak severity,
which is related to the efﬁcacy of treatment. Grade 0 indicates
that the prophylactic immunosuppressive regimen adminis-
tered after the transplant was sufﬁcient to prevent clinical
manifestations of GVHD. Grades I, II, III, and IV indicate that
the immunosuppressive regimen was not sufﬁcient to prevent
clinical manifestations, and higher grades indicate increasing
peak severity. Grade I GVHD indicates that manifestations
were limited to the skin with less than 50% body surface
involvement, and in most cases, the GVHD resolved sponta-
neously. Grade II GVHD indicates limited involvement of the
gastrointestinal tract or liver, or more severe involvement of
the skin, and in most cases, additional immunosuppressive
treatment was sufﬁcient to control disease. Grade III GVHD
indicates more severe involvement of the gastrointestinal
tract or liver, and in many cases, additional treatment did not
readily control the disease. Grade IV GVHD indicates that
GVHD was a major contributing cause of death. Transplant-
related mortality and overall mortality are signiﬁcantly
higher among patients with grades III or IV acute GVHD
compared to those with grades 0, I, or II GVHD. For these
reasons, grades III–IV GVHD has been used as clinically
meaningful endpoint in association analyses.
Figure 1. Long-Range Haplotyping of HLA-A, -B, and -DRB1 in Unrelated Individuals
(A) Schematic illustration of two HLA phenotypically identical individuals with the same or different linkages between HLA-A, -B, and -DRB1 on the MHC
haplotypes.
(B) DNA microarray images of four unrelated donor–recipient pairs from the study population demonstrating MHC haplotype-matched (upper left), and
MHC haplotype-mismatched (HLA-A, upper right; HLA-DRB1, lower left; HLA-A and -DRB1, lower right) relationships. The two haplotypes in each sample
were separated by hybridizing genomic DNA to an array that was spotted with oligonucleotide probes, each specific for one of the two HLA-B alleles in
the sample. After haplotype separation, the HLA-A and HLA-DRB1 alleles carried on each haplotype were identified with the use of 57 HLA-A and 64 HLA-
DRB1 oligonucleotide probes as described [32]. Actual quadruplicate hybridization patterns for 16 of the probes illustrate how the two possible alleles
at each locus could be distinguished from each other. Each column of panels in the figure shows the pattern of probe hybridization with one of the two
MHC haplotypes from each sample. Allele assignments are indicated above each hybridization pattern. The HLA-B probe hybridization patterns validate
the linkage of HLA-B alleles with HLA-A and -DRB1 alleles. Sequences and specificity of probes can be found in [32].
doi:10.1371/journal.pmed.0040008.g001
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MHC Haplotypes in TransplantationStatistical Analyses
We used logistic regression to evaluate the association of
MHC haplotype mismatching with grades III–IV acute
GVHD. Cox regression was used to compare the hazards of
recurrent malignancy, chronic GVHD, mortality, and trans-
plant-related mortality. In addition to haplotype matching,
all regression models contained variables for disease risk,
patient age at transplantation, year of transplantation,
patient/donor gender (female donor for male patient versus
all other combinations), and presence of mismatching at
HLA-DPB1. A test for interaction between number of
common haplotypes and haplotype mismatching was per-
formed by including the term ‘‘number 3 mismatch’’ in the
regression model for GVHD, where ‘‘number’’ represents the
number of common haplotypes modeled as a continuous
linear variable, and ‘‘mismatch’’ is an indicator variable for
haplotype mismatching. This amounted to testing if there
was a linear increase (or decrease) in the odds ratios (ORs) of
acute GVHD for haplotype mismatching compared to
haplotype matching as the number of common haplotypes
ranged from 0 to 2. All reported p-values are two-sided and
were estimated from the Wald test, with no adjustments for
multiple comparisons. Estimates of overall survival were
calculated using the Kaplan–Meier method, and cumulative
incidence estimates were used to summarize the probabilities
of recurrent malignancy and transplant-related mortality.
Death without recurrent malignancy was considered a
competing risk for recurrent malignancy, and recurrent
malignancy was considered a competing risk for transplant-
related mortality.
Results
HLA-A, -B, -DRB1 Linkage
A total of 246 HLA-A, -B, -C, -DRB1, -DQB1 allele-matched
transplants were evaluated in this study (Table 1). Of the 246
donor–recipient pairs, 191 (78%) were haplotype-matched
and 55 (22%) were haplotype-mismatched. The haplotype-
mismatched pairs differed in linkage from HLA-B to HLA-A (n
¼ 18; 33%), from HLA-B to HLA-DRB1 (n ¼ 34; 62%) or from
HLA-B to both HLA-A and -DRB1 (n¼3; 6%). Recipients had a
total of 262 different haplotypes, 197 of which were identiﬁed
only once. Donors had a total of 299 different haplotypes, 239
of which were identiﬁed only once (Table S1).
GVHD
Of the 246 patients in this study, two could not be
evaluated for acute GVHD. One died on day 8 with multi-
organ failure, and the other had recurrent malignancy
without evidence of GVHD on day 19. Among the 244
patients who could be evaluated, the overall probability of
grades III–IV acute GVHD was 34.8%. The probability of
grades III–IV acute GVHD was 26.5% (2.6% grade IV) among
haplotype-matched patients and 63.6% (3.6% grade IV)
among haplotype-mismatched patients (Figure 2A). The
percentages of haplotype-matched patients developing grade
0, I, II, III, and IV acute GVHD were 9.0, 4.0, 60.8, 23.8, and
2.6, respectively. Among haplotype-mismatched patients, the
percentages developing grades 0, I, II, III, and IV were 3.6, 1.8,
30.9, 60.0, and 3.6, respectively. The probability of grades III–
IV acute GVHD was 61% among haplotype-mismatched
patients who differed in linkage from HLA-B to HLA-A and
Table 1. Characteristics of the Study Population
Characteristic Variable Haplotype-Matched
(n ¼ 191)
Haplotype-Mismatched
a
(n ¼ 55)
Median recipient age—y (range) 36.7 (4.4–56.2) 40.4 (1.4–58.7)
Year of transplantation—number (%) 1986–1991 22 (12%) 12 (22%)
1992–1997 93 (49%) 25 (45%)
1998–2003 76 (40%) 18 (33%)
Donor–recipient gender—number (%) Male–male 83 (43%) 23 (42%)
Male–female 46 (24%) 13 (24%)
Female–female 33 (17%) 5 (9%)
Female–male 29 (15%) 14 (25%)
Diagnosis /disease risk
b—number (%) ALL/high, intermediate risk 7 (4%), 18 (9%) 2 (4%), 5 (9%)
AML/high, intermediate risk 10 (5%), 26 (14%) 3 (5%), 1 (2%)
CML/high, intermediate, low risk 5 (3%), 23 (12%), 85 (45%) 0, 15 (27%), 26 (47%)
MDS/high, intermediate risk 9 (5%), 8 (4%) 3 (5%), 0
Mean duration of pre-transplantation CML—d 671 697
Donor–recipient pre-transplantation CMV exposure—number (%) þ/þ 32 (17%) 7 (13%)
þ/  21 (11%) 8 (15%)
 /þ 58 (31%) 19 (35%)
 /  79 (42%) 21 (38%)
Unknown 1 (1%) 0
Number of cells infused per kg body weight— 3 10
8 (range) 3.6 (0.4–32.0) 3.4 (1.1–40.7)
Source of cells—number (%) Bone marrow 167 (87%) 49 (89%)
Peripheral blood stem cells 24 (12%) 6 (11%)
All 246 patients received a myeloablative conditioning regimen, methotrexate and cyclosporine for immunosuppression, and had transplantation from HLA-identical unrelated donors as
described [33,34].
aHaplotype-mismatched pairs differed in linkage from HLA-B to HLA-A (n ¼ 18; 33%), from HLA-B to HLA-DRB1 (n ¼ 34; 62%), or from HLA-B to both HLA-A and -DRB1 (n ¼ 3; 6%).
bDisease risk before transplantation was categorized as low, intermediate, or high according to established criteria [34].
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; MDS, myelodysplastic syndrome.
doi:10.1371/journal.pmed.0040008.t001
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HLA-DRB1.
The unadjusted OR for grades III–IV acute GVHD was 4.87
(95% conﬁdence interval [CI], 2.57–9.20, p , 0.0001) for
haplotype-mismatched patients compared to haplotype-
matched patients. After adjusting for the factors described
above, the OR of grades III–IV acute GVHD was 4.51 (95% CI,
2.34–8.70, p , 0.0001). The odds of GVHD conferred by
haplotype mismatching were similar among patients matched
at HLA-DPB1 and patients mismatched at HLA-DPB1 (ORs of
5.08 and 4.79, respectively).
The strong positive LD across the MHC that accounts for
the association of certain HLA-A, B, and DRB1 alleles on
extended HLA haplotypes is not limited to common HLA
alleles [13,18,20]. To determine whether the rate of haplotype
matching is related to the presence of common haplotypes,
we determined the haplotype match rate among patients with
0, 1, or 2 common haplotypes. Among the 246 patients, 229
(93%) were of Northern European descent and 17 (7%) were
self-designated African, Asian, Hispanic, Native American, or
other racial groups. Statistically inferred haplotypes occur-
ring at a 0.2% or greater frequency in an unrelated donor
population (http://www.nmdpresearch.org/HLA/
em_haplotype_freq.html) were used to group the patients
by the number of common haplotypes. Among the 229
patients of Northern European descent, 45 (19%) had no
common haplotype, 130 (57%) had one, and 54 (24%) had
two. For these three groups, the proportion of haplotype-
matched donor–recipient pairs was 33/45 (73%), 102/130
(78%), and 42/54 (78%), respectively. Among the 17 non-
Northern European patients, the proportion of haplotype-
matched pairs was 3/6, 10/10, and 1/1, respectively.
Previous studies have described the presence of highly
conserved regions between common HLA haplotypes that
share the same HLA alleles [13,19,21,22]. Since haplotype
mismatched pairs share certain HLA alleles and differ for
others, the effect of haplotype mismatching could differ
depending on the degree to which the mismatching hap-
lotypes share conserved regions within the MHC. To address
this question, we examined the association between haplo-
type mismatching and the probability of GVHD according to
the number of common haplotypes. Among all donor–
recipient pairs in the study, the magnitude of the effect of
haplotype mismatching increased as the number of common
haplotypes increased (Table 2), although the ORs were not
Figure 2. Clinical Outcome after Haplotype-Matched (Solid Line) and
Haplotype-Mismatched (Broken Line) Unrelated Donor HCT
All patients in the study were HLA-A, B, C, DRB1, DQB1 allele matched
with their donors.
(A) Probability of grades III–IV acute GVHD.
(B) Probability of recurrent malignancy.
(C) Probability of transplant-related mortality.
(D) Probability of survival.
One patient in the mismatched group had recurrent malignancy at 14.4
y, and one patient in the mismatched group died without recurrent
malignancy at 13.2 y. Seven mismatched patients are alive without
recurrent malignancy from 11.9–14.1 y, and nine mismatched patients
are alive from 11.0–14.5 y. Twenty-three patients in the matched group
are alive without recurrent malignancy from 10.2–18.5 y, and 28 matched
patients are alive from 10.2–18.5 y. Each of these patients is indicated as
censored at 10 y in (B), (C), and (D).
doi:10.1371/journal.pmed.0040008.g002
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or 2 common haplotypes (p ¼ 0.20).
A total of 42 donor–recipient pairs were homozygous at
two or more loci, and could not be tested by our method. Of
these 42 transplants, 12 (28.6%) developed grades III–IV
acute GVHD, an incidence similar to that observed among
the 189 haplotype-matched patients (26.5%).
Compared to haplotype-matched patients, haplotype-mis-
matched patients had an unadjusted hazard ratio (HR) of 1.03
for chronic GVHD (95% CI, 0.69–1.52, p ¼ 0.90) and an
adjusted HR of 1.05 (95% CI, 0.72–1.55, p ¼ 0.79). 14% of
haplotype-matched patients who developed grades III–IV
acute GVHD died before day 100, compared to 11% among
haplotype-mismatched patients.
Recurrent Malignancy and Mortality
The increased risk of grades III–IV acute GVHD was
accompanied by a statistically signiﬁcantly decreased hazard
of recurrent malignancy among haplotype-mismatched pa-
tients compared to haplotype-matched patients (HR 0.45;
95% CI, 0.22–0.92, p ¼ 0.03) (Figure 2B; Table 3).
There was a suggestion of increased risk of transplant-
related mortality with MHC haplotype mismatching, but this
association was not statistically signiﬁcant (HR 1.44; 95% CI,
0.86–2.40, p ¼ 0.17) (Figure 2C; Table 3). Twenty-six of 45
(58%) haplotype-matched patients with grade III acute
GVHD died (19 of the 26 deaths from transplant-related
causes), and 15 of 33 (45%) haplotype-mismatched patients
with grade III acute GVHD died (14 of the 15 deaths from
transplant-related causes). Thirty-one of 50 (62%) haplotype-
matched patients with grades III–IV acute GVHD died (24
deaths without prior disease recurrence), compared to 17 of
35 (49%) haplotype-mismatched patients (16 deaths without
prior disease recurrence). The decrease in recurrent malig-
nancy among haplotype-mismatched patients compared to
haplotype-matched patients coupled with the increase in
severe GVHD led to similar overall survival (Figure 2D) and
adjusted hazards of mortality (HR 0.95; 95% CI, 0.62–1.47, p¼
0.83).
Discussion
In this study of HLA-matched transplant recipients and
donors, haplotype mismatching was associated with a statisti-
cally signiﬁcantly increased risk of severe acute GVHD. These
results indicate that the HLA haplotype can serve as a proxy
for GVHD risk. The advent of the polymerase chain reaction
(PCR) assay in the 1980s ushered in the HLA molecular typing
era and provides the basis for current criteria for donor
selection in support of unrelated HCT (http://www.
worldmarrow.org; http://www.nmdp.org). Although locus-by-
locus matching of donor and recipient HLA alleles can
reduce risks of graft failure and GVHD [28–30], HLA-
identical transplant recipients still suffer from potentially
life-threatening GVHD. Since HLA-matched unrelated do-
nors and recipients are not identical by descent, we
hypothesized that some donor–recipient pairs have identical
MHC haplotypes of physically linked HLA alleles, while
others have different haplotypes. Given the strong LD across
the MHC [5,14,15,19,26], MHC haplotype matching may
predict similarity for the more than 400 immune-related
MHC-resident genes that could cause GVHD. Since it would
not be feasible to assess each MHC polymorphism individu-
ally, we applied classical concepts of LD mapping to measure
haplotype-associated risk [2,3,6].
Family studies are not available for unrelated transplant
donors. Population statistics for individual haplotype infer-
ence may be inaccurate [35], and previously available
laboratory techniques could not be used to deﬁne haplotypes
across large distances within the MHC [24,36]. Application of
our new method uncovered haplotype mismatching in 20%
of HLA allele-matched unrelated pairs. The increment in
GVHD risk associated with haplotype mismatching was at
least comparable in magnitude, if not greater than the
increment associated with a single HLA mismatch among
related HCT recipients [37]. Since the patients and donors
had identical HLA-A, -B, -C, -DRB1, and -DQB1 alleles, GVHD
could not have been caused by disparity for these classical
HLA genes. Furthermore, the magnitude of the effect
associated with haplotype mismatching was similar among
patients matched and mismatched at HLA-DPB1, indicating
that HLA-DPB1 cannot explain the association of haplotype
mismatching with GVHD. These results support the concept
Table 3. Adjusted Effect of HLA-A, -B, -DRB1 Haplotype
Mismatching on Risks of Grades III–IV Acute GVHD, Recurrent
Malignancy, Transplant-Related Mortality, and Mortality after
HCT from HLA-Identical Unrelated Donors
Clinical Outcome OR or HR
a 95% CI p-Value
Grades III–IV acute GVHD 4.51 2.34–8.70 ,0.0001
Recurrent malignancy 0.45 0.22–0.92 0.03
Transplant-related mortality 1.44 0.86–2.40 0.17
Mortality 0.95 0.62–1.47 0.83
Adjusted for patient age, disease severity, patient/donor gender, number of HLA-DPB1
disparities, and year of transplant.
aORs (acute GVHD) and HR (recurrent malignancy, transplant-related mortality, and
mortality) measure risks associated with haplotype mismatching relative to haplotype
matching.
doi:10.1371/journal.pmed.0040008.t003
Table 2. Probability of Grades III–IV Acute GVHD According to
HLA-A, -B, -DRB1 Haplotype Matching and Number of Common
Haplotypes
Number of
Common
Haplotypes
HLA-A, -B,
-DRB1
Haplotype
Proportion with
Grades III–IV
Acute GVHD (%)
OR
a (95% CI)
0 Matched 14/36 (39%) 1
Mismatched 9/15 (60%) 2.36 (0.69–8.08)
1 Matched 25/111 (23%) 1
Mismatched 17/28 (61%) 5.32 (2.21–12.81)
2 Matched 11/42 (26%) 1
Mismatched 9/12 (75%) 8.46 (1.93–37.02)
Statistically inferred haplotypes occurring at a 0.2% or greater frequency in an unrelated
donor population (http://www.nmdpresearch.org/HLA/em_haplotype_freq.html) were
used to group the patients according to the number of common haplotypes.
aORs are unadjusted because the number of patients categorized according to the
number of common haplotypes is too small to accommodate many factors in
multivariable regression models. A test of interaction between haplotype matching and
number of common haplotypes yields p ¼ 0.20 when modeling number of common
haplotypes as a continuous linear variable.
doi:10.1371/journal.pmed.0040008.t002
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e8 0064
MHC Haplotypes in Transplantationthat the MHC harbors additional genes that encode trans-
plantation antigens. Morbidity from GVHD after HCT might
be lowered not only by matching the individual HLA alleles of
the donor and recipient, but also by matching their extended
MHC haplotypes.
The current study was not designed to examine any of the
many genes outside the MHC that could cause GVHD [38].
Since these genes are not HLA linked, it is unlikely that they
could have affected the association between MHC haplotype
mismatching and risk of GVHD observed in the current
study. Included among the many potential non-MHC variants
that could contribute to GVHD are minor histocompatibility
antigens such as those encoded by the Y chromosome when
female donors are used for male recipients, or minor antigens
associated with common HLA alleles such as HLA-A*0201
[39]. Notably, the frequency of HLA-A*0201 and the propor-
tion of gender-mismatched pairs were similar in the
haplotype-matched and haplotype-mismatched groups; fur-
thermore, gender mismatching was included in the regression
models. Therefore, any contribution to GVHD from these
minor antigens would not be expected to inﬂuence the
impact of haplotype mismatching on GVHD risk in the study
population. Finally, HLA-B and -C determinants are known to
serve as ligands for natural killer (NK) cell receptors [40].
Since all study pairs were HLA-B and -C allele matched, and
since the distributions of NK ligands in the haplotype-
matched and haplotype-mismatched groups were similar
(unpublished data), NK ligands cannot explain our ﬁndings.
Mortality after HCT may be caused by transplant-related
complications or by recurrent malignancy. The lack of a
statistically signiﬁcant association of MHC haplotype match-
ing with overall survival was unexpected but may reﬂect the
association of haplotype mismatching predominantly with
clinically severe (grade III) GVHD rather than lethal (grade
IV) GVHD. Even if the use of HLA-matched haplotype-
matched unrelated donors does not improve overall survival,
the effort to avoid or decrease the frequency of severe acute
GVHD could provide clinical beneﬁt. Donor–recipient
haplotype matching may provide a novel strategy to decrease
morbidity from GVHD and may be especially useful for
patients who, because of medical reasons or advanced age,
would not tolerate severe GVHD due to organ toxicity or
prolonged immunosuppressive therapy. The patients in this
study received T-replete unrelated donor grafts. Whether
haplotype matching can further reduce GVHD risk after T
cell–depleted transplantation remains to be determined.
Further studies are warranted to deﬁne potential differences
in the risk of mortality associated with grade III acute GVHD
in haplotype-matched and haplotype-mismatched patients
and to determine whether haplotype mismatching is associ-
ated with adverse outcomes after HCT with other preparative
regimens, sources of stem cells, and immunosuppressive
regimens.
Among haplotype-mismatched recipients, the increased
risk of GVHD was offset by a lower risk of recurrent
malignancy. Whether the lower risk of recurrent malignancy
among haplotype-mismatched patients can be attributed to
an increased risk of GVHD (through graft-versus-leukemia
effects) or to causes that do not involve GVHD remains to be
addressed in a larger transplant population [41]. At present,
additional pharmacologic or immunotherapeutic strategies
may be necessary in order to optimize overall transplant
outcome if haplotype-matched donors are selected as a way of
decreasing morbidity and mortality from GVHD in patients
at high risk of recurrent malignancy after HCT.
The determinants that contribute to GVHD risk after
haplotype-mismatched transplantation could be located any-
where within the gene-rich MHC, and the effects could arise
from either disparity between the donor and recipient
haplotype-linked variation or from the direct effects of the
variation itself. Previous studies have delineated the sequence
of several well-known common HLA haplotypes [13,16,19–
22]. Haplotypes that share the same alleles at a given HLA
locus also share highly conserved segments or blocks of
sequences in strong LD with the HLA allele. Thus, the degree
of similarity between haplotype-mismatched combinations
could vary considerably, and certain regions within the MHC
may contribute different levels of GVHD risk associated with
haplotype mismatching. If common haplotypes are more
highly conserved for undetected variation in certain regions
of the MHC than others, then the effect of haplotype
mismatching on GVHD among patients with common
haplotypes might be greater than the effect among patients
with no common haplotypes, as suggested by our current
results. If future studies with larger numbers of patients
validate this hypothesis, the results would suggest that efforts
to identify haplotype-matched donors would provide the
greatest level of protection against GVHD in the subpopu-
lation of patients with two common haplotypes.
An important question is whether transplant outcomes can
be improved by matching for selected regions of HLA
haplotypes that contribute the highest risk of GVHD. Addi-
tional technology will be needed to allow all haplotype-
associated MHC genes to be tested for their individual
contributions to GVHD risk, and a very large cohort will be
needed to answer this question. At present, the similarity of
GVHD probabilities in patients whose haplotypes differed
from HLA-B to HLA-A and from HLA-B to HLA-DRB1 suggests
that GVHD-risk genes are located both telomeric and
centromeric to HLA-B. Furthermore, among the 191 hap-
lotype-matched pairs, only four differed in linkage from HLA-
B to HLA-C, and no cases differed in linkage from HLA-DRB1
to HLA-DQB1 (unpublished data). These results suggest that
nearly all haplotype-matched pairs had identical ﬁve-locus
haplotypes and that HLA-C and HLA-DQB1 provide addi-
tional markers for narrowing the potential regions of
interest. Candidates include any gene-encoding polymorphic
determinants that can function as transplantation antigens
[14,16,17,19,42]. If only a few genes contribute to the
increased risk of GVHD in haplotype-mismatched patients,
reﬁnement of our haplotyping method to include informative
MHC class I, II, and III markers could be used to narrow the
boundaries of GVHD-risk regions, allowing smaller regions to
be examined at a higher level of genomic discrimination
[14,19,26,42].
Speciﬁc regions of mismatching between the donor and
recipient MHC haplotypes might also have different effects
on the risk of recurrent malignancy. In the current study, the
limited numbers of class I and class II haplotype-mismatched
patients precluded any informative analysis of the association
of recurrent malignancy with class I versus class II haplotype
mismatching. Information from future studies showing
differences in the risk of recurrent malignancy associated
with haplotype mismatching for speciﬁc MHC regions could
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toward decreasing the risk of acute GVHD while preserving
graft-versus-leukemia effects.
Regardless of the number, nature, and location of GVHD-
risk genes within the MHC, the results of the current study
demonstrate that the three-locus HLA-A, -B, -DRB1 haplotype
can serve as a proxy for GVHD risk. The ease of our
haplotyping technique focused on only three genetic markers
could provide clinicians with a simple tool for GVHD risk
assessment and a means to decrease GVHD-associated
morbidity after unrelated HCT. In the future, more reﬁned
mapping of GVHD-risk determinants will provide important
information as to whether matching for certain regions of
haplotypes will be clinically important.
Currently, patients with common HLA alleles in strong LD
have the highest chances of identifying HLA allele-matched
donors. We were interested in addressing whether the
presence of common haplotypes in a recipient could be used
as a predictor of haplotype matching, since this information
has practical implications in the search for unrelated donors.
Among the entire study population, the rate of haplotype
matching was 78% for patients with two common haplotypes,
80% for those with one, and 71% for those with none (Table
2). Although the number of study participants was limited,
these data suggest that allele frequency is only one parameter
of successful donor haplotype matching.
Strong positive LD between low-frequency alleles increases
the chance that a haplotype-matched donor might be
identiﬁed for a given patient. For the 55 haplotype-
mismatched patients in our study, a repeated search of the
Bone Marrow Donors Worldwide database (http://www.bmdw.
org) identiﬁed between four and 1,777 (median: 65) potential
HLA-A, -B, -DRB1-matched donors per patient. For the 45
patients of Northern European descent with two uncommon
haplotypes, a repeated search identiﬁed up to 321 (median:
14) potential HLA-A, -B, -DRB1-matched donors per patient.
One patient had a single donor, and only one patient had no
other potential donors. These observations suggest that most
ﬁve-locus-matched Northern European patients have several
potential donors who could be prospectively haplotyped.
Development of strategies to maximize the identiﬁcation of
potential haplotype-matched donors among the 10 million
volunteer donors worldwide (http://www.bmdw.org; http://
www.nmdp.org) and to direct donor recruitment efforts in
a way that provides optimal size and composition of registries
([43,44]; http://www.worldmarrow.org) will be important re-
search questions for the future.
Haplotypes have very high utility in hypothesis-driven and
exploratory gene mapping. Our method for long-range
haplotype deﬁnition could be used to assess the clinical
importance of haplotypes in solid organ transplantation [27]
and to discover genes that predispose to autoimmunity,
infection, and cancer [23,25,45–47]. This method offers the
potential for disease-association mapping without the need
for individual tagSNP selection. Previous studies have been
confounded by strong LD, which makes it difﬁcult to
determine whether disease susceptibility is conferred by the
marker gene itself or by another gene in LD with the marker
gene. Our haplotyping method will not surmount the
problem of strongly linked genes, but it could be used to
clarify physical linkages that differ between cases and
controls and permit the measurement of independent effects.
The ability to isolate high-quality intact genomic DNA for
extended haplotyping provides an approach for screening
causative variants even if the full extent of human haplotype
diversity and structure are yet to be uncovered.
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Background. Graft rejection and graft-versus-host disease (GVHD) are
feared complications of hematopoietic cell transplantation (HCT). GVHD
can affect all parts of the body, and, if severe (grade III to IV out of a scale
of IV), can lead to the death of the transplant recipient. GVHD or
rejection of the graft occurs when there are differences in specific
proteins involved in the immune response (known as HLA antigens)
between donor and recipient that stimulate the immune reaction. GVHD
and graft rejection occur most often in people who receive transplants
from unrelated donors because, although when donors are matched to
recipients matching is done for the most important HLA antigens known
to be involved, it has not technically been possible to match for all
possible antigens. However, the human genome is organized into
segments or blocks of closely linked genetic variants that are inherited as
‘‘haplotypes’’ on the same DNA strand of a chromosome. Most of the
genes that code for HLA antigens are physically located together in one
part of the human genome, known as the MHC region. Currently three
HLA markers from this region (HLA-A, -B, -DRB1) are matched when
matching donors and recipients. If it were possible to better map the
structure of this region, it would be possible to better match recipients
and donors (especially unrelated donors) for the unidentified trans-
plantation antigens and reduce the chance of recipients getting GVHD or
rejecting their grafts.
Why Was This Study Done? Current strategies to define MHC haplotype
blocks look at, on average, a length of only 18,000 base pairs and hence
cannot define extended MHC haplotypes. Previously, this group of
researchers developed a method of defining the HLA-A, B, DR haplotypes
in recipients and their HLA-matched unrelated transplant donors using
high-quality DNA containing 2 million base pairs across the MHC region.
They wanted see if using this technique might provide a way to better
assess the risk recipients have of developing GVHD or of having recurrent
disease.
What Did the Researchers Do and Find? They studied 246 HCT
recipients and their donors who had been matched for HLA-A, -B, -C,
-DRB1, -DQB1 by current techniques. The recipients were having HCT for
a variety of hematological cancers: acute lymphoid leukemia, acute
myeloid leukemia, chronic myeloid leukemia, or myelodysplastic
syndrome. They found that, using the new technique, 22% of the
donor–recipient pairs were haplotype-mismatched. Taking various other
factors into account, including age, and patient and donor gender, MHC
haplotype mismatching was associated with an approximately four times
greater risk of severe acute GVHD but with a lower risk of disease
recurrence. The lower risk of recurrence is believed to be because
transplanted cells do not only replace abnormal cancerous cells but also
react against them and therefore decrease the chance of the cancer
recurring; mismatched cells are known to be more stimulated to react
against the cancerous cells.
What Do These Findings Mean? The results here suggest that this new
haplotype matching method can provide a way to assess the risk of
GVHD after HCT from unrelated donors, and in future could be
considered as a technique to match donors and recipients.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040008.
  Medline Plus has a page of information on stem cell transplantation,
including HCT
  The Anthony Nolan Trust holds one of the largest databases of
unrelated donors in the world
  The National Cancer Institute has a page of questions and answers on
HCT
  The Center for International Blood & Marrow Transplant Research
describes outcomes research in transplantation
  The National Marrow Donor Program describes how HLA-typed
unrelated donors are identified
  The World Marrow Donor Association is involved in facilitating stem
cell donation across international boundaries
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